Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia

References

• StroupTSMcEvoyJPSwartzMSThe National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developmentSchizophr Bull2003291153112908658
   PubMed Web of Science ®Google Scholar
• BuckleyPFBroad therapeutic uses of atypical antipsychotic medicationsBiol Psychiatry2001501191292411743945
   PubMed Web of Science ®Google Scholar
• SongWSChaJHYoonSHChoYSParkKYKimMHThe atypical antipsychotic olanzapine disturbs depotentiation by modulating mAChRs and impairs reversal learningNeuropharmacology201711411127866902
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKomossaKSchwarzSHead-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysisSchizophr Res20101232–322523320692814
   PubMed Web of Science ®Google Scholar
• KinonBJKaiserCJAhmedSRotelliMDKollack-WalkerSAssociation between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disordersJ Clin Psychopharmacol200525325525815876905
   PubMed Web of Science ®Google Scholar
• EversSSCalcagnoliFvan DijkGScheurinkAJOlanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar ratsPharmacol Biochem Behav201097116316920570692
   PubMed Web of Science ®Google Scholar
• EversSSBoersmaGJTamashiroKLScheurinkAJvan DijkGRoman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expressionJ Psychopharmacol201731111437145228892416
   PubMed Web of Science ®Google Scholar
• MadhusoodananSParidaSJimenezCHyperprolactinemia associated with psychotropics – a reviewHum Psychopharmacol201025428129720521318
   PubMed Web of Science ®Google Scholar
• FraguasDCorrellCUMerchán-NaranjoJEfficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisonsEur Neuropsychopharmacol201121862164520702068
   PubMed Web of Science ®Google Scholar
• SuzukiYFukuiNWatanabeJGender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patientsProg Neuropsychopharmacol Biol Psychiatry20103471266126820621147
   PubMed Web of Science ®Google Scholar
• SuzukiYSugaiTFukuiNDifferences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychoticsSchizophr Res20131451–311611923375624
   PubMed Web of Science ®Google Scholar
• SawamuraKSuzukiYFukuiNSugaiTSomeyaTGender differences in prolactin elevation induced by olanzapine in Japanese drug-naïve schizophrenic patientsProg Neuropsychopharmacol Biol Psychiatry20063081511151416824658
   PubMed Web of Science ®Google Scholar
• SmithSWheelerMJMurrayRO’KeaneVThe effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axisJ Clin Psychopharmacol200222210911411910254
   PubMed Web of Science ®Google Scholar
• MargariLMateraEPetruzzelliMGProlactin variations during risperidone therapy in a sample of drug-naive children and adolescentsInt Clin Psychopharmacol201530210310825514607
   PubMed Web of Science ®Google Scholar
• SkredeSGonzález-GarcíaIMartinsLLack of ovarian secretions reverts the anabolic action of olanzapine in female ratsInt J Neuropsychopharmacol201720121005101229020342
   PubMed Web of Science ®Google Scholar
• ZhuYKrauseMHuhnMAntipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analysesLancet Psychiatry20174969470528736102
   PubMed Web of Science ®Google Scholar
• DayabandaraMHanwellaRRatnatungaSSeneviratneSSuraweeraCde SilvaVAAntipsychotic-associated weight gain: management strategies and impact on treatment adherenceNeuropsychiatr Dis Treat2017132231224128883731
   PubMed Web of Science ®Google Scholar
• SongXFanXZhangJProlactin serum levels correlate with inflammatory status in drug-naïve first-episode schizophreniaWorld J Biol Psychiatry201415754655224959913
   PubMed Web of Science ®Google Scholar
• DruytsEEapenSWuPThorlundKThe risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysisSyst Rev2014311625312992
   PubMedGoogle Scholar
• PetrikisPTigasSTzallasATArchimandritiDTSkapinakisPMavreasVProlactin levels in drug-naïve patients with schizophrenia and other psychotic disordersInt J Psychiatry Clin Pract201620316516927334805
   PubMed Web of Science ®Google Scholar
• SuzukiYOnoSSugaiTDose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophreniaHum Psychopharmacol201126644044321823168
   PubMed Web of Science ®Google Scholar
• NoelMBWoodsideBEffects of systemic and central prolactin injections on food intake, weight gain, and estrous cyclicity in female ratsPhysiol Behav19935411511548327594
   PubMed Web of Science ®Google Scholar
• Gerardo-GettensTMooreBJSternJSHorwitzBAProlactin stimulates food intake in a dose-dependent mannerAm J Physiol19892561 Pt 2R276R2802912221
   PubMed Web of Science ®Google Scholar
• GreenmanYTordjmanKSternNIncreased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levelsClin Endocrinol1998485547553
   PubMed Web of Science ®Google Scholar
• NunesMCSobrinhoLGCalhaz-JorgeCSantosMAMauricioJCSousaMFPsychosomatic factors in patients with hyperprolactinemia and/or galactorrheaObstet Gynecol19805555915957189268
   PubMed Web of Science ®Google Scholar
• TekCKucukgoncuSGuloksuzSWoodsSWSrihariVHAnnamalaiAAntipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medicationsEarly Interv Psychiatry201610319320225962699
   PubMed Web of Science ®Google Scholar
• LeuchtSCiprianiASpineliLComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet2013382989695196223810019
   PubMed Web of Science ®Google Scholar
• LordCCWylerSCWanRThe atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2CJ Clin Invest201712793402340628805659
   PubMed Web of Science ®Google Scholar
• AlbayrakYBeyazyüzMBeyazyüzEKuloğluMIncreased serum prolactin levels in drug-naive first-episode male patients with schizophreniaNord J Psychiatry201468534134624094029
   PubMed Web of Science ®Google Scholar
• ShrivastavaAJohnstonMBureauYShahNBaseline serum prolactin in drug-naïve, first-episode schizophrenia and outcome at five years: Is it a predictive factor?Innovat Clin Neurosci2012941721
   Google Scholar
• AstonJRechsteinerEBullNBorgwardtSGschwandtnerURiecher-RösslerAHyperprolactinaemia in early psychosis-not only due to antipsychoticsProg Neuropsychopharmacol Biol Psychiatry20103471342134420188136
   PubMed Web of Science ®Google Scholar
• ShrivastavaATamhaneMSerum prolactin level and severity of psychopathology in patients of schizophreniaIndian J Psychiatry2000421485121407907
   PubMedGoogle Scholar
• RoelfsemaFPijlHKeenanDMVeldhuisJDProlactin secretion in healthy adults is determined by gender, age and body mass indexPLoS One201272e3130522363612
   PubMed Web of Science ®Google Scholar
• HuangMYuLPanFA randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patientsProg Neuropsychopharmacol Biol Psychiatry20188112213029097257
   PubMed Web of Science ®Google Scholar